Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | PREP | P48147 | 4/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29428754 | 1.00 | CHRM2 (0.50) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL26197651 | 1.00 | CHRM2 (0.50) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL29231997 | 1.00 | CHRM2 (0.50) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL29344038 | 1.00 | CHRM2 (0.50) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL33372530 | 1.00 | CHRM2 (0.50) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL25324203 | 0.86 | CHRM2 (0.47) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL26196638 | 0.86 | CHRM2 (0.47) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL402018 | 0.84 | CHRM2 (0.59) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL3935909 | 0.84 | CHRM2 (0.59) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL14410734 | 0.84 | CHRM2 (0.59) | CHRM2CHRM1CHRM3PREPNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4216951-B1 | KRAS G12D INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20230357277-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-11-09 | — | — | US | disclosed |
| EP-4216951-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022066646-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357277-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | CHRM2 4884/4885CHRM1 4881/4885CHRM3 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.